cd5l Search Results


94
MedChemExpress rcd5l
Rcd5l, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd5l/CD5L%2C+Mouse/10__2139_slash_ssrn__4714411-98-29-31
Average 94 stars, based on 1 article reviews
rcd5l - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

91
Cusabio human cd5l
a Plasma <t>CD5L</t> concentration of CAA patients ( N = 12) and HC ( N = 12) as well as CAA models ( N = 5 in each group) and WT C57/BL6 mice ( N = 5). Data are presented as mean values ± SEM with the indicated significance (by two-tailed Student’s t test). b Left: CD5L deposition in mice brain was evaluated with immunostaining. Right: Immunostaining of CD31 (red), CD5L (green), C5b-9 (blue) and TSPAN4 (purple). Data are representative of 4 biologically independent experiments. c Plasma C5-9 concentration of mice. N = 6 in PBS-M, Aβ40-M and CD5L KO Aβ40-M transferred mice and N = 5 in CD5L KO PBS-M treated group. Data are presented as mean values ± SEM with the indicated significance (by one-way ANOVA followed by Tukey’s post-test). d C5b-9 deposition in brain as assessed with immunostaining. Data are representative of 3 biologically independent experiments. e Fluorescent intensity of 3kDa-Dextran in the plasma and eyeballs of the recipients. N = 6 in PBS-M, Aβ40-M and CD5L KO Aβ40-M transferred mice and N = 5 in CD5L KO PBS-M treated group. Data are presented as mean values ± SEM with the indicated significance (by one-way ANOVA followed by Tukey’s post-test). f Leakage of 3kDa-Dextran in brain parenchyma was assessed with fluorescent microscopy. Data are representative of 3 biologically independent experiments. g Coronal brain sections of the recipients were subjected to immunostaining of CD31 (green) and ZO-1 (red). Data are representative of 3 biologically independent experiments. h Skin autopsy sample of a CAA patient (Left) and brain tissue of WT and Tg-SwDI/B +/+ mice (24w of age) (Right) were subjected to IEM with CD5L staining. Blue dash lines outline micro-vessel wall. Red stars emphasize blood vessel lumen. Red arrow heads emphasize peri-vessel macrophages. Red arrows emphasize CD5L deposition in blood vessels within migrasome-like structures. Data are representative of 3 biologically independent experiments. Source data are provided as a Source Data file.
Human Cd5l, supplied by Cusabio, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd5l/CD5L/pmc10319857-514-14-20
Average 91 stars, based on 1 article reviews
human cd5l - by Bioz Stars, 2026-11
91/100 stars
  Buy from Supplier

94
R&D Systems primary anti cd5l antibody
Serum proteins separated by two dimensional gel electrophoresis in early and advanced NAFLD, with and without HCC . These are representative blots comparing immune depleted and desalted serum from a patient with NAFLD and no fibrosis, a patient with NAFLD cirrhosis, and a patient with NAFLD cirrhosis and cancer. Serum profiles separated by 2D gel electrophoresis from 5 patients in each group, run in duplicate, were compared using Progenesis software. 5 spots were characterised by MS after excision. Spots 1,2 and 3 were isoforms of apolipoprotein A1, spot 4 was apolipoprotein A4, and spot 5 was identified as CD5 antigen like, or <t>CD5L.</t>
Primary Anti Cd5l Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd5l/CD5L+Antibody/pmc02729079-82-20-23
Average 94 stars, based on 1 article reviews
primary anti cd5l antibody - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

93
R&D Systems distinct csf pools
Serum proteins separated by two dimensional gel electrophoresis in early and advanced NAFLD, with and without HCC . These are representative blots comparing immune depleted and desalted serum from a patient with NAFLD and no fibrosis, a patient with NAFLD cirrhosis, and a patient with NAFLD cirrhosis and cancer. Serum profiles separated by 2D gel electrophoresis from 5 patients in each group, run in duplicate, were compared using Progenesis software. 5 spots were characterised by MS after excision. Spots 1,2 and 3 were isoforms of apolipoprotein A1, spot 4 was apolipoprotein A4, and spot 5 was identified as CD5 antigen like, or <t>CD5L.</t>
Distinct Csf Pools, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd5l/Recombinant+Mouse+CD5L+Protein%2C+CF/pmc09893943-214-27-35
Average 93 stars, based on 1 article reviews
distinct csf pools - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

94
R&D Systems biotin conjugated anti cd5l
Serum proteins separated by two dimensional gel electrophoresis in early and advanced NAFLD, with and without HCC . These are representative blots comparing immune depleted and desalted serum from a patient with NAFLD and no fibrosis, a patient with NAFLD cirrhosis, and a patient with NAFLD cirrhosis and cancer. Serum profiles separated by 2D gel electrophoresis from 5 patients in each group, run in duplicate, were compared using Progenesis software. 5 spots were characterised by MS after excision. Spots 1,2 and 3 were isoforms of apolipoprotein A1, spot 4 was apolipoprotein A4, and spot 5 was identified as CD5 antigen like, or <t>CD5L.</t>
Biotin Conjugated Anti Cd5l, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd5l/CD5L+Antibody+%5BBiotin%5D/pmc07933155-298-22-24
Average 94 stars, based on 1 article reviews
biotin conjugated anti cd5l - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

85
Thermo Fisher gene exp cd5l mm00437567 m1
Serum proteins separated by two dimensional gel electrophoresis in early and advanced NAFLD, with and without HCC . These are representative blots comparing immune depleted and desalted serum from a patient with NAFLD and no fibrosis, a patient with NAFLD cirrhosis, and a patient with NAFLD cirrhosis and cancer. Serum profiles separated by 2D gel electrophoresis from 5 patients in each group, run in duplicate, were compared using Progenesis software. 5 spots were characterised by MS after excision. Spots 1,2 and 3 were isoforms of apolipoprotein A1, spot 4 was apolipoprotein A4, and spot 5 was identified as CD5 antigen like, or <t>CD5L.</t>
Gene Exp Cd5l Mm00437567 M1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 85/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd5l/Gene+Exp%2E+Cd5l%2C+Mm00437567_m1/pm39760211-118-22-6
Average 85 stars, based on 1 article reviews
gene exp cd5l mm00437567 m1 - by Bioz Stars, 2026-11
85/100 stars
  Buy from Supplier

93
R&D Systems anti cd5l antibody
( A ) The EMARS products for serum EVs from EML4-ALK transgenic mouse. To average experimental results over each group, an aliquot of the serum (10 μL each) from 10 animals in each group (WT), large lung tumor-bearing (TL), and small lung tumor-bearing mice (TS) was mixed in equal proportions, and then applied to EV purification and EMARS. The EMARS products were concentrated and purified by immunoprecipitation with the anti-fluorescein antibody Sepharose. The resulting samples were subjected to SDS-PAGE analysis with fluorescence detection. “IP” indicates the immunoprecipitated samples, and “Lys” indicates the lysate samples before immunoprecipitation. The right panel indicates the same gel as the left panel, but exposed for a longer time. ( B ) Confirmation of candidate partner molecules <t>(CD5L</t> and PZP) with mouse CHL1 in EVs. The EMARS products of WT, TL, and TS were respectively applied to immunoprecipitation (anti-fluorescence antibody Sepharose) and western blot analysis with anti-CD5L (left panel) antibody. After the stripping as described in the “ Materials and methods ”, the membranes were re-stained with anti-PZP antibody (right panel). Arrows indicate the detected band of CD5L and PZP proteins (including predicted dimer). Asterisk indicates unknown bands (predicted as non-specific or partial fragments). ( C, D ) Confirmation of candidate partner molecules (SLC4A1 and THBS1) with mouse CHL1 in EVs. The western blot analysis was performed with anti-SLC4A1 antibody ( C ). After stripping, the membranes were re-stained with anti-THBS1 antibody ( D ). Arrows indicate the detected band of SLC4A1 and THBS1 proteins (including predicted dimers). Asterisks indicate unknown bands (predicted as non-specific or partial fragments). ( E ) Expression of SLC4A1 (left column) and CHL1 proteins (right column) in tumor tissues from two male and two female EML4-ALK transgenic mice. The fragments of lung cancer tissues were mashed and washed gently with PBS, and then lysed with SDS-PAGE sample buffer directly. The resulting samples were subjected to Western blot analysis with anti-SLC4A1 antibody and anti-CHL1 antibody. Arrows indicate the detected band of monomer SLC4A1 and CHL1 proteins.
Anti Cd5l Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd5l/Mouse+CD5L+Antibody/bio_rxiv__2020__07__23__217018-88-78-81
Average 93 stars, based on 1 article reviews
anti cd5l antibody - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

90
OriGene first strand cdna synthesis system
( A ) The EMARS products for serum EVs from EML4-ALK transgenic mouse. To average experimental results over each group, an aliquot of the serum (10 μL each) from 10 animals in each group (WT), large lung tumor-bearing (TL), and small lung tumor-bearing mice (TS) was mixed in equal proportions, and then applied to EV purification and EMARS. The EMARS products were concentrated and purified by immunoprecipitation with the anti-fluorescein antibody Sepharose. The resulting samples were subjected to SDS-PAGE analysis with fluorescence detection. “IP” indicates the immunoprecipitated samples, and “Lys” indicates the lysate samples before immunoprecipitation. The right panel indicates the same gel as the left panel, but exposed for a longer time. ( B ) Confirmation of candidate partner molecules <t>(CD5L</t> and PZP) with mouse CHL1 in EVs. The EMARS products of WT, TL, and TS were respectively applied to immunoprecipitation (anti-fluorescence antibody Sepharose) and western blot analysis with anti-CD5L (left panel) antibody. After the stripping as described in the “ Materials and methods ”, the membranes were re-stained with anti-PZP antibody (right panel). Arrows indicate the detected band of CD5L and PZP proteins (including predicted dimer). Asterisk indicates unknown bands (predicted as non-specific or partial fragments). ( C, D ) Confirmation of candidate partner molecules (SLC4A1 and THBS1) with mouse CHL1 in EVs. The western blot analysis was performed with anti-SLC4A1 antibody ( C ). After stripping, the membranes were re-stained with anti-THBS1 antibody ( D ). Arrows indicate the detected band of SLC4A1 and THBS1 proteins (including predicted dimers). Asterisks indicate unknown bands (predicted as non-specific or partial fragments). ( E ) Expression of SLC4A1 (left column) and CHL1 proteins (right column) in tumor tissues from two male and two female EML4-ALK transgenic mice. The fragments of lung cancer tissues were mashed and washed gently with PBS, and then lysed with SDS-PAGE sample buffer directly. The resulting samples were subjected to Western blot analysis with anti-SLC4A1 antibody and anti-CHL1 antibody. Arrows indicate the detected band of monomer SLC4A1 and CHL1 proteins.
First Strand Cdna Synthesis System, supplied by OriGene, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd5l/Cd5l+Mouse+siRNA+Oligo+Duplex/pm23811687-463-26-30
Average 90 stars, based on 1 article reviews
first strand cdna synthesis system - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

93
ABclonal Biotechnology rabbit anti mouse cd5l
<t>CD5L</t> promotes the uptake of free fatty acids (FFAs) by hepatocytes and stellate cells. A: Uptake of BODIPY-labeled palmitate acid (BODIPY-PA) in a time-dependent manner. Top four panels: Images taken at indicated time of PA exposure. Bottom panel: Quantitative analysis of the images. B: Cultured mouse hepatocytes ( top panel ) and HepG2 cells ( bottom panel ) were pretreated with CD5L (2000 ng/mL) or vehicle for 25 minutes. Uptake of free fatty acids was then measured by incubating BODIPY-PA for the indicated period. CD5L pretreatment enhanced the uptake of BODIPY-PA with 0.25, 0.5, and 1 hour of uptake but not 2 and 4 hours of uptake. C: Cultured LX-2 cells were pretreated with CD5L (2000 ng/mL) or vehicle for 25 minutes. Uptake of free fatty acids was then measured by incubating BODIPY-PA for the indicated period. CD5L pretreatment facilitated the uptake of BODIPY-PA with 15 minutes, 30 minutes, and 1 hour of uptake but not 2 and 4 hours of uptake. No differences were observed with 4 hours of uptake. ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001, and ∗∗∗∗ P < 0.0001. Scale bars = 50 μm ( A ). NS, not significant.
Rabbit Anti Mouse Cd5l, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd5l/CD5L+Rabbit+pAb/pmc12597548-39-5-11
Average 93 stars, based on 1 article reviews
rabbit anti mouse cd5l - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

93
R&D Systems human rcd5l
Fig. 4. Recombinant CD5L <t>(rCD5L)</t> suppresses TGFβ-mediated fibrogenic responses in human lung fibroblast cells. Protein levels of COL1A1, FN1, and α-SMA in IMR-90 cells pre-treated with vehicle or rCD5L (0.4 μg/mL) for 3 h, followed by treatment with vehicle or TGFβ (2 ng/mL) for a further 24 h. Representative blots and quantification relative to α-tubulin are shown. Unpaired two-sample Student’s t-test (2-tailed) was used to analyze the difference between rCD5L-treated and vehicle-treated cells, either without or with TGFβ treatment.
Human Rcd5l, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd5l/Recombinant+Human+CD5L+Protein%2C+CF/pm40544764-40-0-3
Average 93 stars, based on 1 article reviews
human rcd5l - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

92
Cusabio differentiation 5 antigen like cd5l kits
The Up-Regulated and Down-Regulated Top 5 Proteins Between the Two Groups
Differentiation 5 Antigen Like Cd5l Kits, supplied by Cusabio, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd5l/Human+CD5+Antigen-like(CD5L)+ELISA+Kit/pmc10859095-112-16-66
Average 92 stars, based on 1 article reviews
differentiation 5 antigen like cd5l kits - by Bioz Stars, 2026-11
92/100 stars
  Buy from Supplier

93
R&D Systems cd5l antibody
Characterization of myeloid cell subsets and identification of CD5L⁺ macrophages as potential migrasome-responsive cells. ( A ) UMAP visualization showing the reclustering of myeloid cells into 10 distinct subpopulations. ( B ) Heatmap displaying the expression profiles of representative marker genes for each myeloid subset. ( C ) Bar plot showing the relative abundance of each myeloid subpopulation in normoxic versus hypoxic migrasome-treated groups. A notable 8-fold increase in the proportion of CD5L⁺ macrophages was observed in the hypoxic group. ( D ) Gene Set Variation Analysis (GSVA) indicating significant activation of the complement signaling pathway in CD5L⁺ macrophages. ( E ) Chord diagram depicting inferred cell–cell communication networks, highlighting potential interactions between CD5L⁺ macrophages and fibroblasts, T cells, and other immune cells via GDF signaling. ( F ) Activation IGF signaling pathway network mediated crosstalk between CD5L⁺ macrophages and epithelial tumor cells. ( G ) In the IGF signaling pathway network, CD5L⁺ macrophages exhibit specific overexpression of IGF1. ( H ) Among the six macrophage cell-types, CD5L⁺ macrophages exhibit specific overexpression of <t>CD5L</t>
Cd5l Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd5l/Mouse+CD5L+Biotinylated+Antibody/pmc12683794-146-20-23
Average 93 stars, based on 1 article reviews
cd5l antibody - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

Image Search Results


a Plasma CD5L concentration of CAA patients ( N = 12) and HC ( N = 12) as well as CAA models ( N = 5 in each group) and WT C57/BL6 mice ( N = 5). Data are presented as mean values ± SEM with the indicated significance (by two-tailed Student’s t test). b Left: CD5L deposition in mice brain was evaluated with immunostaining. Right: Immunostaining of CD31 (red), CD5L (green), C5b-9 (blue) and TSPAN4 (purple). Data are representative of 4 biologically independent experiments. c Plasma C5-9 concentration of mice. N = 6 in PBS-M, Aβ40-M and CD5L KO Aβ40-M transferred mice and N = 5 in CD5L KO PBS-M treated group. Data are presented as mean values ± SEM with the indicated significance (by one-way ANOVA followed by Tukey’s post-test). d C5b-9 deposition in brain as assessed with immunostaining. Data are representative of 3 biologically independent experiments. e Fluorescent intensity of 3kDa-Dextran in the plasma and eyeballs of the recipients. N = 6 in PBS-M, Aβ40-M and CD5L KO Aβ40-M transferred mice and N = 5 in CD5L KO PBS-M treated group. Data are presented as mean values ± SEM with the indicated significance (by one-way ANOVA followed by Tukey’s post-test). f Leakage of 3kDa-Dextran in brain parenchyma was assessed with fluorescent microscopy. Data are representative of 3 biologically independent experiments. g Coronal brain sections of the recipients were subjected to immunostaining of CD31 (green) and ZO-1 (red). Data are representative of 3 biologically independent experiments. h Skin autopsy sample of a CAA patient (Left) and brain tissue of WT and Tg-SwDI/B +/+ mice (24w of age) (Right) were subjected to IEM with CD5L staining. Blue dash lines outline micro-vessel wall. Red stars emphasize blood vessel lumen. Red arrow heads emphasize peri-vessel macrophages. Red arrows emphasize CD5L deposition in blood vessels within migrasome-like structures. Data are representative of 3 biologically independent experiments. Source data are provided as a Source Data file.

Journal: Nature Communications

Article Title: Macrophage lineage cells-derived migrasomes activate complement-dependent blood-brain barrier damage in cerebral amyloid angiopathy mouse model

doi: 10.1038/s41467-023-39693-x

Figure Lengend Snippet: a Plasma CD5L concentration of CAA patients ( N = 12) and HC ( N = 12) as well as CAA models ( N = 5 in each group) and WT C57/BL6 mice ( N = 5). Data are presented as mean values ± SEM with the indicated significance (by two-tailed Student’s t test). b Left: CD5L deposition in mice brain was evaluated with immunostaining. Right: Immunostaining of CD31 (red), CD5L (green), C5b-9 (blue) and TSPAN4 (purple). Data are representative of 4 biologically independent experiments. c Plasma C5-9 concentration of mice. N = 6 in PBS-M, Aβ40-M and CD5L KO Aβ40-M transferred mice and N = 5 in CD5L KO PBS-M treated group. Data are presented as mean values ± SEM with the indicated significance (by one-way ANOVA followed by Tukey’s post-test). d C5b-9 deposition in brain as assessed with immunostaining. Data are representative of 3 biologically independent experiments. e Fluorescent intensity of 3kDa-Dextran in the plasma and eyeballs of the recipients. N = 6 in PBS-M, Aβ40-M and CD5L KO Aβ40-M transferred mice and N = 5 in CD5L KO PBS-M treated group. Data are presented as mean values ± SEM with the indicated significance (by one-way ANOVA followed by Tukey’s post-test). f Leakage of 3kDa-Dextran in brain parenchyma was assessed with fluorescent microscopy. Data are representative of 3 biologically independent experiments. g Coronal brain sections of the recipients were subjected to immunostaining of CD31 (green) and ZO-1 (red). Data are representative of 3 biologically independent experiments. h Skin autopsy sample of a CAA patient (Left) and brain tissue of WT and Tg-SwDI/B +/+ mice (24w of age) (Right) were subjected to IEM with CD5L staining. Blue dash lines outline micro-vessel wall. Red stars emphasize blood vessel lumen. Red arrow heads emphasize peri-vessel macrophages. Red arrows emphasize CD5L deposition in blood vessels within migrasome-like structures. Data are representative of 3 biologically independent experiments. Source data are provided as a Source Data file.

Article Snippet: Concentration of mouse NEFL (FineTest, EM1688), mouse C5b-9 (FineTest, EM1392), mouse CD5L (Boster, EK1414), human CD5L (MEIMIAN, MM-50587H1), human Aβ40 (CUSABIO, CSB-E08299h), human Aβ42 (MAI Bio, LM-2685H), and human C5b-9 (FineTest, EH3858) in plasma was assessed with commercial kits according to instructions of manufacturers.

Techniques: Clinical Proteomics, Concentration Assay, Two Tailed Test, Immunostaining, Microscopy, Staining

Serum proteins separated by two dimensional gel electrophoresis in early and advanced NAFLD, with and without HCC . These are representative blots comparing immune depleted and desalted serum from a patient with NAFLD and no fibrosis, a patient with NAFLD cirrhosis, and a patient with NAFLD cirrhosis and cancer. Serum profiles separated by 2D gel electrophoresis from 5 patients in each group, run in duplicate, were compared using Progenesis software. 5 spots were characterised by MS after excision. Spots 1,2 and 3 were isoforms of apolipoprotein A1, spot 4 was apolipoprotein A4, and spot 5 was identified as CD5 antigen like, or CD5L.

Journal: BMC Cancer

Article Title: A proteomic strategy to identify novel serum biomarkers for liver cirrhosis and hepatocellular cancer in individuals with fatty liver disease

doi: 10.1186/1471-2407-9-271

Figure Lengend Snippet: Serum proteins separated by two dimensional gel electrophoresis in early and advanced NAFLD, with and without HCC . These are representative blots comparing immune depleted and desalted serum from a patient with NAFLD and no fibrosis, a patient with NAFLD cirrhosis, and a patient with NAFLD cirrhosis and cancer. Serum profiles separated by 2D gel electrophoresis from 5 patients in each group, run in duplicate, were compared using Progenesis software. 5 spots were characterised by MS after excision. Spots 1,2 and 3 were isoforms of apolipoprotein A1, spot 4 was apolipoprotein A4, and spot 5 was identified as CD5 antigen like, or CD5L.

Article Snippet: A direct ELISA for novel candidate CD5L was optimised using different concentrations of serum (raw, 1;10, 1:100, 1:500 and 1:1000), primary anti-CD5L antibody (R&D systems) and recombinant CD5L protein (R&D systems).

Techniques: Two-Dimensional Gel Electrophoresis, Electrophoresis, Software

CD5L discriminates poorly between cirrhotic patients with and without HCC . Serum levels of CD5L were measured by ELISA assay in cirrhotic patients with (218 ± 221; n = 45) and without (194 ± 166; n = 49) HCC, as shown in 2A. Characteristics of the individuals are shown in Table 1. There was no significant difference between the two groups. ROC analyses is shown in 2B. The area under the curve is 0.495 (95% confidence intervals 0.376 and 0.614). A level > 400 ng/ml has a sensitivity of only 20%, but a specificity of 88%. Levels > 500 ng/ml have a specificity of 96%, > 600 ng/ml of 98% and > 700 ng/ml of 100%. For comparison, the mean CD5L serum level from patients without cirrhosis (detailed in figure 3) is also shown.

Journal: BMC Cancer

Article Title: A proteomic strategy to identify novel serum biomarkers for liver cirrhosis and hepatocellular cancer in individuals with fatty liver disease

doi: 10.1186/1471-2407-9-271

Figure Lengend Snippet: CD5L discriminates poorly between cirrhotic patients with and without HCC . Serum levels of CD5L were measured by ELISA assay in cirrhotic patients with (218 ± 221; n = 45) and without (194 ± 166; n = 49) HCC, as shown in 2A. Characteristics of the individuals are shown in Table 1. There was no significant difference between the two groups. ROC analyses is shown in 2B. The area under the curve is 0.495 (95% confidence intervals 0.376 and 0.614). A level > 400 ng/ml has a sensitivity of only 20%, but a specificity of 88%. Levels > 500 ng/ml have a specificity of 96%, > 600 ng/ml of 98% and > 700 ng/ml of 100%. For comparison, the mean CD5L serum level from patients without cirrhosis (detailed in figure 3) is also shown.

Article Snippet: A direct ELISA for novel candidate CD5L was optimised using different concentrations of serum (raw, 1;10, 1:100, 1:500 and 1:1000), primary anti-CD5L antibody (R&D systems) and recombinant CD5L protein (R&D systems).

Techniques: Enzyme-linked Immunosorbent Assay, Comparison

CD5L discriminates between steatohepatitis patients with and without cirrhosis . Serum levels of CD5L were measured in a total of 113 patients with either ALD or NAFLD. Fibrosis was scored histologically on liver biopsy as per the Brunt scoring system. The numbers of individuals in each group are shown within the boxes of chart 3A. The difference in CD5L levels between the different stages of fibrosis is statistically significant by univariate analysis (p = 0.004) controlled for both age and sex. This difference The ROC analyses for the identification of those individuals with stage 4 fibrosis (cirrhosis) is depicted in 3B. The area under the curve is 0.719 (95% confidence intervals 0.623 and 0.816), p < 0.0001. A level of CD5L 50 ng/ml has a sensitivity of 78% and a specificity of 46%, while a level of 100 ng/ml has a sensitivity of 63% and a specificity of 72%. A level greater than 200 ng/ml has a specificity of 95% (sensitivity 41%), and greater than 300 ng/ml of 97% (sensitivity 27%).

Journal: BMC Cancer

Article Title: A proteomic strategy to identify novel serum biomarkers for liver cirrhosis and hepatocellular cancer in individuals with fatty liver disease

doi: 10.1186/1471-2407-9-271

Figure Lengend Snippet: CD5L discriminates between steatohepatitis patients with and without cirrhosis . Serum levels of CD5L were measured in a total of 113 patients with either ALD or NAFLD. Fibrosis was scored histologically on liver biopsy as per the Brunt scoring system. The numbers of individuals in each group are shown within the boxes of chart 3A. The difference in CD5L levels between the different stages of fibrosis is statistically significant by univariate analysis (p = 0.004) controlled for both age and sex. This difference The ROC analyses for the identification of those individuals with stage 4 fibrosis (cirrhosis) is depicted in 3B. The area under the curve is 0.719 (95% confidence intervals 0.623 and 0.816), p < 0.0001. A level of CD5L 50 ng/ml has a sensitivity of 78% and a specificity of 46%, while a level of 100 ng/ml has a sensitivity of 63% and a specificity of 72%. A level greater than 200 ng/ml has a specificity of 95% (sensitivity 41%), and greater than 300 ng/ml of 97% (sensitivity 27%).

Article Snippet: A direct ELISA for novel candidate CD5L was optimised using different concentrations of serum (raw, 1;10, 1:100, 1:500 and 1:1000), primary anti-CD5L antibody (R&D systems) and recombinant CD5L protein (R&D systems).

Techniques:

CD5L mRNA expression is not altered in association with either fat, inflammation or fibrosis scores in pre-cirrhotic NAFLD liver tissues . mRNA CD5L expression was quantified by real-time PCR, relative to GAPDH and a normal liver sample, in 21 pre-cirrhotic NAFLD biopsy tissues, 13 normal liver samples taken at the time of liver resection, one cirrhotic liver and one HCC. As shown in 4A-C, there was no difference in any pre-cirrhotic NAFLD biopsy tissues in association with the degree of fat, inflammation or fibrosis. There was a significant increase in the NAFLD tissues as a group (n = 21), compared with normal liver tissues (n = 13) as represented in 4D (6.945 ± 0.722 versus1.68 ± 0.269; p = 0.000, ***). The elevated CD5L mRNA expression in one cirrhotic and HCC tissue pair, obtained at the time of laparoscopic radiofrequency ablation, is also presented in 4C and is in keeping with the elevated serum CD5L levels identified in the larger cohort of patients studied.

Journal: BMC Cancer

Article Title: A proteomic strategy to identify novel serum biomarkers for liver cirrhosis and hepatocellular cancer in individuals with fatty liver disease

doi: 10.1186/1471-2407-9-271

Figure Lengend Snippet: CD5L mRNA expression is not altered in association with either fat, inflammation or fibrosis scores in pre-cirrhotic NAFLD liver tissues . mRNA CD5L expression was quantified by real-time PCR, relative to GAPDH and a normal liver sample, in 21 pre-cirrhotic NAFLD biopsy tissues, 13 normal liver samples taken at the time of liver resection, one cirrhotic liver and one HCC. As shown in 4A-C, there was no difference in any pre-cirrhotic NAFLD biopsy tissues in association with the degree of fat, inflammation or fibrosis. There was a significant increase in the NAFLD tissues as a group (n = 21), compared with normal liver tissues (n = 13) as represented in 4D (6.945 ± 0.722 versus1.68 ± 0.269; p = 0.000, ***). The elevated CD5L mRNA expression in one cirrhotic and HCC tissue pair, obtained at the time of laparoscopic radiofrequency ablation, is also presented in 4C and is in keeping with the elevated serum CD5L levels identified in the larger cohort of patients studied.

Article Snippet: A direct ELISA for novel candidate CD5L was optimised using different concentrations of serum (raw, 1;10, 1:100, 1:500 and 1:1000), primary anti-CD5L antibody (R&D systems) and recombinant CD5L protein (R&D systems).

Techniques: Expressing, Real-time Polymerase Chain Reaction

The identification of the differentiating protein spots on 2D gels.

Journal: BMC Cancer

Article Title: A proteomic strategy to identify novel serum biomarkers for liver cirrhosis and hepatocellular cancer in individuals with fatty liver disease

doi: 10.1186/1471-2407-9-271

Figure Lengend Snippet: The identification of the differentiating protein spots on 2D gels.

Article Snippet: A direct ELISA for novel candidate CD5L was optimised using different concentrations of serum (raw, 1;10, 1:100, 1:500 and 1:1000), primary anti-CD5L antibody (R&D systems) and recombinant CD5L protein (R&D systems).

Techniques: Sequencing

( A ) The EMARS products for serum EVs from EML4-ALK transgenic mouse. To average experimental results over each group, an aliquot of the serum (10 μL each) from 10 animals in each group (WT), large lung tumor-bearing (TL), and small lung tumor-bearing mice (TS) was mixed in equal proportions, and then applied to EV purification and EMARS. The EMARS products were concentrated and purified by immunoprecipitation with the anti-fluorescein antibody Sepharose. The resulting samples were subjected to SDS-PAGE analysis with fluorescence detection. “IP” indicates the immunoprecipitated samples, and “Lys” indicates the lysate samples before immunoprecipitation. The right panel indicates the same gel as the left panel, but exposed for a longer time. ( B ) Confirmation of candidate partner molecules (CD5L and PZP) with mouse CHL1 in EVs. The EMARS products of WT, TL, and TS were respectively applied to immunoprecipitation (anti-fluorescence antibody Sepharose) and western blot analysis with anti-CD5L (left panel) antibody. After the stripping as described in the “ Materials and methods ”, the membranes were re-stained with anti-PZP antibody (right panel). Arrows indicate the detected band of CD5L and PZP proteins (including predicted dimer). Asterisk indicates unknown bands (predicted as non-specific or partial fragments). ( C, D ) Confirmation of candidate partner molecules (SLC4A1 and THBS1) with mouse CHL1 in EVs. The western blot analysis was performed with anti-SLC4A1 antibody ( C ). After stripping, the membranes were re-stained with anti-THBS1 antibody ( D ). Arrows indicate the detected band of SLC4A1 and THBS1 proteins (including predicted dimers). Asterisks indicate unknown bands (predicted as non-specific or partial fragments). ( E ) Expression of SLC4A1 (left column) and CHL1 proteins (right column) in tumor tissues from two male and two female EML4-ALK transgenic mice. The fragments of lung cancer tissues were mashed and washed gently with PBS, and then lysed with SDS-PAGE sample buffer directly. The resulting samples were subjected to Western blot analysis with anti-SLC4A1 antibody and anti-CHL1 antibody. Arrows indicate the detected band of monomer SLC4A1 and CHL1 proteins.

Journal: bioRxiv

Article Title: Bimolecule detection for Extracellular Vesicle Screening

doi: 10.1101/2020.07.23.217018

Figure Lengend Snippet: ( A ) The EMARS products for serum EVs from EML4-ALK transgenic mouse. To average experimental results over each group, an aliquot of the serum (10 μL each) from 10 animals in each group (WT), large lung tumor-bearing (TL), and small lung tumor-bearing mice (TS) was mixed in equal proportions, and then applied to EV purification and EMARS. The EMARS products were concentrated and purified by immunoprecipitation with the anti-fluorescein antibody Sepharose. The resulting samples were subjected to SDS-PAGE analysis with fluorescence detection. “IP” indicates the immunoprecipitated samples, and “Lys” indicates the lysate samples before immunoprecipitation. The right panel indicates the same gel as the left panel, but exposed for a longer time. ( B ) Confirmation of candidate partner molecules (CD5L and PZP) with mouse CHL1 in EVs. The EMARS products of WT, TL, and TS were respectively applied to immunoprecipitation (anti-fluorescence antibody Sepharose) and western blot analysis with anti-CD5L (left panel) antibody. After the stripping as described in the “ Materials and methods ”, the membranes were re-stained with anti-PZP antibody (right panel). Arrows indicate the detected band of CD5L and PZP proteins (including predicted dimer). Asterisk indicates unknown bands (predicted as non-specific or partial fragments). ( C, D ) Confirmation of candidate partner molecules (SLC4A1 and THBS1) with mouse CHL1 in EVs. The western blot analysis was performed with anti-SLC4A1 antibody ( C ). After stripping, the membranes were re-stained with anti-THBS1 antibody ( D ). Arrows indicate the detected band of SLC4A1 and THBS1 proteins (including predicted dimers). Asterisks indicate unknown bands (predicted as non-specific or partial fragments). ( E ) Expression of SLC4A1 (left column) and CHL1 proteins (right column) in tumor tissues from two male and two female EML4-ALK transgenic mice. The fragments of lung cancer tissues were mashed and washed gently with PBS, and then lysed with SDS-PAGE sample buffer directly. The resulting samples were subjected to Western blot analysis with anti-SLC4A1 antibody and anti-CHL1 antibody. Arrows indicate the detected band of monomer SLC4A1 and CHL1 proteins.

Article Snippet: After blocking with 5% skim milk solution, transferred membrane was reacted with first antibodies as follows: anti-mouse and human CHL1 antibody (AF2147 and MAB2126; R&D systems, MN; 1 μg/ml), HRP-conjugated anti-mouse and human CHL1 antibody (described above), anti-α2 integrin antibody (ab133557; Abcam; 1 μg/ml), anti-β1 integrin antibody (610467; BD transduction laboratories, NJ; 0.25 μg/ml), anti-FGFR3 antibody (c-15; Santa cruz, TX; 0.2 μg/ml 5% BSA-PBS), anti-TSG101 antibody (EXOAB-TSG101-1; System Biosciences, CA; 1:500), anti-CD63 antibody (EXOAB-CD63A-1; System Biosciences, CA; 1:500), anti-CD5L antibody (AF2834; R&D systems, MN; 0.4 μg/ml), anti-Pregnancy Zone Protein (PZP) antibody (PAG324Ra01; CLOUD-CLONE, TX; 0.5 μg/ml), anti-SLC4A1 antibody (18566-1-AP; PROTEINTECH, IL; 0.6 μg/ml), anti-Thrombospondin 1 (THBS1) antibody (PAA611Hu01; CLOUD-CLONE, TX; 0.5 μg/ml), and anti-caspase 14 antibody (MAB8215; R&D systems, MN; 0.5 μg/ml).

Techniques: Transgenic Assay, Purification, Immunoprecipitation, SDS Page, Fluorescence, Western Blot, Stripping Membranes, Staining, Expressing

CD5L promotes the uptake of free fatty acids (FFAs) by hepatocytes and stellate cells. A: Uptake of BODIPY-labeled palmitate acid (BODIPY-PA) in a time-dependent manner. Top four panels: Images taken at indicated time of PA exposure. Bottom panel: Quantitative analysis of the images. B: Cultured mouse hepatocytes ( top panel ) and HepG2 cells ( bottom panel ) were pretreated with CD5L (2000 ng/mL) or vehicle for 25 minutes. Uptake of free fatty acids was then measured by incubating BODIPY-PA for the indicated period. CD5L pretreatment enhanced the uptake of BODIPY-PA with 0.25, 0.5, and 1 hour of uptake but not 2 and 4 hours of uptake. C: Cultured LX-2 cells were pretreated with CD5L (2000 ng/mL) or vehicle for 25 minutes. Uptake of free fatty acids was then measured by incubating BODIPY-PA for the indicated period. CD5L pretreatment facilitated the uptake of BODIPY-PA with 15 minutes, 30 minutes, and 1 hour of uptake but not 2 and 4 hours of uptake. No differences were observed with 4 hours of uptake. ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001, and ∗∗∗∗ P < 0.0001. Scale bars = 50 μm ( A ). NS, not significant.

Journal: The American Journal of Pathology

Article Title: Characterizing Kupffer Cell Production of CD5 Antigen-Like and Its Function on Regulating Migration of Natural Killer T Cells

doi: 10.1016/j.ajpath.2025.06.003

Figure Lengend Snippet: CD5L promotes the uptake of free fatty acids (FFAs) by hepatocytes and stellate cells. A: Uptake of BODIPY-labeled palmitate acid (BODIPY-PA) in a time-dependent manner. Top four panels: Images taken at indicated time of PA exposure. Bottom panel: Quantitative analysis of the images. B: Cultured mouse hepatocytes ( top panel ) and HepG2 cells ( bottom panel ) were pretreated with CD5L (2000 ng/mL) or vehicle for 25 minutes. Uptake of free fatty acids was then measured by incubating BODIPY-PA for the indicated period. CD5L pretreatment enhanced the uptake of BODIPY-PA with 0.25, 0.5, and 1 hour of uptake but not 2 and 4 hours of uptake. C: Cultured LX-2 cells were pretreated with CD5L (2000 ng/mL) or vehicle for 25 minutes. Uptake of free fatty acids was then measured by incubating BODIPY-PA for the indicated period. CD5L pretreatment facilitated the uptake of BODIPY-PA with 15 minutes, 30 minutes, and 1 hour of uptake but not 2 and 4 hours of uptake. No differences were observed with 4 hours of uptake. ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001, and ∗∗∗∗ P < 0.0001. Scale bars = 50 μm ( A ). NS, not significant.

Article Snippet: Then, cells were treated with rabbit anti-mouse CD5L as primary antibody (ABclonal, Woburn, MA) and BV421 labeled donkey anti-rabbit IgG as the secondary antibody (clone: Poly4064; BioLegend) subsequently.

Techniques: Labeling, Cell Culture

Expression of Cd5l in liver tissues from mouse models of steatotic liver injury. A: Expression of Cd5l is concurrently induced with Clec4f , a marker for liver macrophages in high-fat diet (HFD) induced steatotic livers. Low-fat diet (LFD) serves as control. B: Expression of Cd5l and Clec4f in ethanol (EtOH) induced steatotic livers. C : Expression of Cd5l and Clec4f in steatotic livers induced by high-fat and high-sucrose (HFHC) feeding versus normal chow (NC) control. D : Expression of Cd5l in steatohepatitis LiPten livers. E: Correlation of Clec4f and Cd5l expression in all mice analyzed in A – D regardless of diet and genotype. ∗ P < 0.05, ∗∗ P < 0.01, and ∗∗∗ P < 0.001. Con, control.

Journal: The American Journal of Pathology

Article Title: Characterizing Kupffer Cell Production of CD5 Antigen-Like and Its Function on Regulating Migration of Natural Killer T Cells

doi: 10.1016/j.ajpath.2025.06.003

Figure Lengend Snippet: Expression of Cd5l in liver tissues from mouse models of steatotic liver injury. A: Expression of Cd5l is concurrently induced with Clec4f , a marker for liver macrophages in high-fat diet (HFD) induced steatotic livers. Low-fat diet (LFD) serves as control. B: Expression of Cd5l and Clec4f in ethanol (EtOH) induced steatotic livers. C : Expression of Cd5l and Clec4f in steatotic livers induced by high-fat and high-sucrose (HFHC) feeding versus normal chow (NC) control. D : Expression of Cd5l in steatohepatitis LiPten livers. E: Correlation of Clec4f and Cd5l expression in all mice analyzed in A – D regardless of diet and genotype. ∗ P < 0.05, ∗∗ P < 0.01, and ∗∗∗ P < 0.001. Con, control.

Article Snippet: Then, cells were treated with rabbit anti-mouse CD5L as primary antibody (ABclonal, Woburn, MA) and BV421 labeled donkey anti-rabbit IgG as the secondary antibody (clone: Poly4064; BioLegend) subsequently.

Techniques: Expressing, Marker, Control

Identification of Clec4f + liver macrophages (LMacs) as the dominant cell population expressing CD5L in the liver. A: Analysis of CD5L in all CD45 + cell populations identified a CD5L hi versus a CD5L low population. B: Analysis of CD11b and F4/80 in all CD45 + cell populations to identify CD11b hi F4/80 low (yellow) versus CD11b intermediate F4/80 hi (red) population LMacs. C: Overlay of A and B shows that CD5L hi population overlaps with CD11b intermediate F4/80 hi population LMacs. D: Analysis of CD5L and CLEC4F shows CD5L high expression cells also express high CLEC4F. E: Quantification of CD5L expression in the two LMac populations in LiPten versus control mouse livers. ∗∗ P < 0.01, ∗∗∗∗ P < 0.0001. FSC, forward scatter; MFI, mean fluorescent intensity.

Journal: The American Journal of Pathology

Article Title: Characterizing Kupffer Cell Production of CD5 Antigen-Like and Its Function on Regulating Migration of Natural Killer T Cells

doi: 10.1016/j.ajpath.2025.06.003

Figure Lengend Snippet: Identification of Clec4f + liver macrophages (LMacs) as the dominant cell population expressing CD5L in the liver. A: Analysis of CD5L in all CD45 + cell populations identified a CD5L hi versus a CD5L low population. B: Analysis of CD11b and F4/80 in all CD45 + cell populations to identify CD11b hi F4/80 low (yellow) versus CD11b intermediate F4/80 hi (red) population LMacs. C: Overlay of A and B shows that CD5L hi population overlaps with CD11b intermediate F4/80 hi population LMacs. D: Analysis of CD5L and CLEC4F shows CD5L high expression cells also express high CLEC4F. E: Quantification of CD5L expression in the two LMac populations in LiPten versus control mouse livers. ∗∗ P < 0.01, ∗∗∗∗ P < 0.0001. FSC, forward scatter; MFI, mean fluorescent intensity.

Article Snippet: Then, cells were treated with rabbit anti-mouse CD5L as primary antibody (ABclonal, Woburn, MA) and BV421 labeled donkey anti-rabbit IgG as the secondary antibody (clone: Poly4064; BioLegend) subsequently.

Techniques: Expressing, Control

Colocalization of CD5L with CLEC4F in mouse livers. A: Immunofluorescence staining of CD5L and CLEC4F in LiPten versus genotype control (Con) livers showing more CD5L and CLEC4F staining in the injured livers of LiPten mice. Most CD5L is colocalized in cell expression CLEC4F. Blue, DAPI for nuclei. Quantification of positively stained cells. Boxed areas are shown in the bottom three panels as enlarged images. Arrows point to CD5L and CLEC4F positive stained cells. B: Three random sections per animal were counted for double-stained cells versus total CLEC4F staining cells in the LiPten and control mice. The fold change difference between LiPten livers and controls is reported. C: Expression of Clec4f , Cd5l , and TimD4 in livers of mice treated with clodronate (CLD) to depleted macrophages. D: Alamar Blue fluorescent signal in Raw264.7 cells treated with 250 μmol/L palmitic acid with or without CD5L (2000 ng/mL). n = 3 ( B ). ∗ P < 0.05, ∗∗∗∗ P < 0.0001. Scale bars = 100 μm ( A ). PBS, phosphate-buffered saline.

Journal: The American Journal of Pathology

Article Title: Characterizing Kupffer Cell Production of CD5 Antigen-Like and Its Function on Regulating Migration of Natural Killer T Cells

doi: 10.1016/j.ajpath.2025.06.003

Figure Lengend Snippet: Colocalization of CD5L with CLEC4F in mouse livers. A: Immunofluorescence staining of CD5L and CLEC4F in LiPten versus genotype control (Con) livers showing more CD5L and CLEC4F staining in the injured livers of LiPten mice. Most CD5L is colocalized in cell expression CLEC4F. Blue, DAPI for nuclei. Quantification of positively stained cells. Boxed areas are shown in the bottom three panels as enlarged images. Arrows point to CD5L and CLEC4F positive stained cells. B: Three random sections per animal were counted for double-stained cells versus total CLEC4F staining cells in the LiPten and control mice. The fold change difference between LiPten livers and controls is reported. C: Expression of Clec4f , Cd5l , and TimD4 in livers of mice treated with clodronate (CLD) to depleted macrophages. D: Alamar Blue fluorescent signal in Raw264.7 cells treated with 250 μmol/L palmitic acid with or without CD5L (2000 ng/mL). n = 3 ( B ). ∗ P < 0.05, ∗∗∗∗ P < 0.0001. Scale bars = 100 μm ( A ). PBS, phosphate-buffered saline.

Article Snippet: Then, cells were treated with rabbit anti-mouse CD5L as primary antibody (ABclonal, Woburn, MA) and BV421 labeled donkey anti-rabbit IgG as the secondary antibody (clone: Poly4064; BioLegend) subsequently.

Techniques: Immunofluorescence, Staining, Control, Expressing, Saline

CD5L promotes chemotaxis of natural killer T (NKT) cells. A: Schematics of the Transwell assay. B: Transwell assay performed with primary liver immune cells in the insert with or without 2000 ng/mL CD5L in the bottom chamber. No CD5L wells contain media and 0.1% fetal bovine serum (FBS). Cells recovered in the bottom were analyzed for immune cell types using flow cytometry and reported as percentage of cell distributions. C: Transwell assay performed with primary liver immune cells in the insert with or without liver macrophage (LMac) in the bottom chamber. No LMac wells contain media and 0.1% FBS. Cells recovered in the bottom were analyzed for immune cell types using flow cytometry and reported as percentage of cell distributions. Each dot is one mouse. Data are not significant (NS), P = 0.057. D: Transwell assay performed with Jurkat cells in the insert and 2% FBS with indicated doses of CD5L in the bottom chamber. E: Transwell assay performed with primary liver immune cells in the insert and LMac in the bottom chamber. Treatment with or without CD5L neutralizing antibody or CD36 inhibitor SMS121 is compared with vehicle treatment (0.1% FBS). F: Schematic representation of the overall function of CD5L in the liver: CD5L produced by LMacs facilitates lipid uptake in hepatocytes and stellate cells and regulates the migration of NKT cells. G: Correlation of CD5L with Nk1.1, a marker of NKT in liver injury models. ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001, and ∗∗∗∗ P < 0.0001; # P < 0.05 only detected in experimental group.

Journal: The American Journal of Pathology

Article Title: Characterizing Kupffer Cell Production of CD5 Antigen-Like and Its Function on Regulating Migration of Natural Killer T Cells

doi: 10.1016/j.ajpath.2025.06.003

Figure Lengend Snippet: CD5L promotes chemotaxis of natural killer T (NKT) cells. A: Schematics of the Transwell assay. B: Transwell assay performed with primary liver immune cells in the insert with or without 2000 ng/mL CD5L in the bottom chamber. No CD5L wells contain media and 0.1% fetal bovine serum (FBS). Cells recovered in the bottom were analyzed for immune cell types using flow cytometry and reported as percentage of cell distributions. C: Transwell assay performed with primary liver immune cells in the insert with or without liver macrophage (LMac) in the bottom chamber. No LMac wells contain media and 0.1% FBS. Cells recovered in the bottom were analyzed for immune cell types using flow cytometry and reported as percentage of cell distributions. Each dot is one mouse. Data are not significant (NS), P = 0.057. D: Transwell assay performed with Jurkat cells in the insert and 2% FBS with indicated doses of CD5L in the bottom chamber. E: Transwell assay performed with primary liver immune cells in the insert and LMac in the bottom chamber. Treatment with or without CD5L neutralizing antibody or CD36 inhibitor SMS121 is compared with vehicle treatment (0.1% FBS). F: Schematic representation of the overall function of CD5L in the liver: CD5L produced by LMacs facilitates lipid uptake in hepatocytes and stellate cells and regulates the migration of NKT cells. G: Correlation of CD5L with Nk1.1, a marker of NKT in liver injury models. ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001, and ∗∗∗∗ P < 0.0001; # P < 0.05 only detected in experimental group.

Article Snippet: Then, cells were treated with rabbit anti-mouse CD5L as primary antibody (ABclonal, Woburn, MA) and BV421 labeled donkey anti-rabbit IgG as the secondary antibody (clone: Poly4064; BioLegend) subsequently.

Techniques: Chemotaxis Assay, Transwell Assay, Flow Cytometry, Produced, Migration, Marker

Elevated plasma CD5L in high-fat diet (HFD)–induced liver injury and its association with hepatocellular carcinoma (HCC) response to immune checkpoint therapy. A: Plasma concentration of CD5L in patients with HCC versus healthy donors. A and B: Plasma concentration of CD5L is higher in patients with HCC with higher Child Pugh scores ( B ) versus lower scores ( A ). C: Plasma concentration of CD5L predicts patient response to therapy. Left panel: Plasma CD5L in patients showed clinical benefit versus those who did not show clinical benefit. Right panel: Plasma CD5L in patients who responded completely or partially versus those whose disease did not progress or progressed. Red dotted line shows a trend of progression. Data are not significant (NS), P = 0.0748. D: Plasma alanine aminotransferase (ALT) levels in mice fed low-fat diet (LFD) versus HFD at the indicated time points. Each dot represents one mouse. E: Detection of CD5L in serum of mice fed LFD versus HFD. HFD feeding for 5 and 9 months significantly increased the plasma levels of CD5l. Each dot represents one mouse. n = 50 patients with HCC ( A ); n = 5 healthy donors ( A ); n = 1 patient who responded completely ( C , right panel ); n = 8 patients who responded partially and patients whose disease progressed ( C , right panel ); n = 27 patients whose disease did not progress ( C , right panel ). ∗ P < 0.05, ∗∗∗ P < 0.001. CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease.

Journal: The American Journal of Pathology

Article Title: Characterizing Kupffer Cell Production of CD5 Antigen-Like and Its Function on Regulating Migration of Natural Killer T Cells

doi: 10.1016/j.ajpath.2025.06.003

Figure Lengend Snippet: Elevated plasma CD5L in high-fat diet (HFD)–induced liver injury and its association with hepatocellular carcinoma (HCC) response to immune checkpoint therapy. A: Plasma concentration of CD5L in patients with HCC versus healthy donors. A and B: Plasma concentration of CD5L is higher in patients with HCC with higher Child Pugh scores ( B ) versus lower scores ( A ). C: Plasma concentration of CD5L predicts patient response to therapy. Left panel: Plasma CD5L in patients showed clinical benefit versus those who did not show clinical benefit. Right panel: Plasma CD5L in patients who responded completely or partially versus those whose disease did not progress or progressed. Red dotted line shows a trend of progression. Data are not significant (NS), P = 0.0748. D: Plasma alanine aminotransferase (ALT) levels in mice fed low-fat diet (LFD) versus HFD at the indicated time points. Each dot represents one mouse. E: Detection of CD5L in serum of mice fed LFD versus HFD. HFD feeding for 5 and 9 months significantly increased the plasma levels of CD5l. Each dot represents one mouse. n = 50 patients with HCC ( A ); n = 5 healthy donors ( A ); n = 1 patient who responded completely ( C , right panel ); n = 8 patients who responded partially and patients whose disease progressed ( C , right panel ); n = 27 patients whose disease did not progress ( C , right panel ). ∗ P < 0.05, ∗∗∗ P < 0.001. CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease.

Article Snippet: Then, cells were treated with rabbit anti-mouse CD5L as primary antibody (ABclonal, Woburn, MA) and BV421 labeled donkey anti-rabbit IgG as the secondary antibody (clone: Poly4064; BioLegend) subsequently.

Techniques: Clinical Proteomics, Concentration Assay

Fig. 4. Recombinant CD5L (rCD5L) suppresses TGFβ-mediated fibrogenic responses in human lung fibroblast cells. Protein levels of COL1A1, FN1, and α-SMA in IMR-90 cells pre-treated with vehicle or rCD5L (0.4 μg/mL) for 3 h, followed by treatment with vehicle or TGFβ (2 ng/mL) for a further 24 h. Representative blots and quantification relative to α-tubulin are shown. Unpaired two-sample Student’s t-test (2-tailed) was used to analyze the difference between rCD5L-treated and vehicle-treated cells, either without or with TGFβ treatment.

Journal: Biochemical and biophysical research communications

Article Title: CD5L is a target of transcription factor Nrf2.

doi: 10.1016/j.bbrc.2025.152225

Figure Lengend Snippet: Fig. 4. Recombinant CD5L (rCD5L) suppresses TGFβ-mediated fibrogenic responses in human lung fibroblast cells. Protein levels of COL1A1, FN1, and α-SMA in IMR-90 cells pre-treated with vehicle or rCD5L (0.4 μg/mL) for 3 h, followed by treatment with vehicle or TGFβ (2 ng/mL) for a further 24 h. Representative blots and quantification relative to α-tubulin are shown. Unpaired two-sample Student’s t-test (2-tailed) was used to analyze the difference between rCD5L-treated and vehicle-treated cells, either without or with TGFβ treatment.

Article Snippet: Human rCD5L (2797-CL, R&D Systems) was reconstituted in sterile PBS.

Techniques: Recombinant

The Up-Regulated and Down-Regulated Top 5 Proteins Between the Two Groups

Journal: Journal of Inflammation Research

Article Title: Serum Proteomic Analysis Revealed Biomarkers for Eosinophilic Chronic Rhinosinusitis with Nasal Polyps Pathophysiology

doi: 10.2147/JIR.S444280

Figure Lengend Snippet: The Up-Regulated and Down-Regulated Top 5 Proteins Between the Two Groups

Article Snippet: Mannose receptor C-type 1 (MRC1) kits (Cat: CSB-E09961h), cadherin 13 (CDH13) kits (Cat: CSB-E13817h), cluster of differentiation 5 antigen-like (CD5L) kits (Cat: CSB-E13423h), matrix metalloproteinase-2 (MMP2) kits (Cat: CSB-E04675h), plasma protease C1 inhibitor (SERPING1) kits (Cat: CSB-EL021086HU), insulin-like growth factor-binding protein 5 (IGFBP5) kits (Cat: CSB-EL010901HU), tripartite motif-containing protein 28 (TRIM28) kits (Cat: CSB-EL024502HU), and fatty acid-binding protein 5 (FABP5) kits (Cat: CSB-EL007946HU) were purchased from Cusabio (Wuhan, China).

Techniques: Clinical Proteomics

Validation of the top 5 up and down-regulated proteins in an independent validation cohort. ( A – E ) comparison of serum MRC1, CDH13, LTA4H, CD5L and MMP2 concentrations between the eCRSwNP and neCRSwNP groups. ( F – J ) comparison of serum SERPING1, IGFBP5, TRIM28, CHL1 and FABP5 levels between the eCRSwNP and neCRSwNP groups. *P<0.05; **P<0.01; ***P<0.001.

Journal: Journal of Inflammation Research

Article Title: Serum Proteomic Analysis Revealed Biomarkers for Eosinophilic Chronic Rhinosinusitis with Nasal Polyps Pathophysiology

doi: 10.2147/JIR.S444280

Figure Lengend Snippet: Validation of the top 5 up and down-regulated proteins in an independent validation cohort. ( A – E ) comparison of serum MRC1, CDH13, LTA4H, CD5L and MMP2 concentrations between the eCRSwNP and neCRSwNP groups. ( F – J ) comparison of serum SERPING1, IGFBP5, TRIM28, CHL1 and FABP5 levels between the eCRSwNP and neCRSwNP groups. *P<0.05; **P<0.01; ***P<0.001.

Article Snippet: Mannose receptor C-type 1 (MRC1) kits (Cat: CSB-E09961h), cadherin 13 (CDH13) kits (Cat: CSB-E13817h), cluster of differentiation 5 antigen-like (CD5L) kits (Cat: CSB-E13423h), matrix metalloproteinase-2 (MMP2) kits (Cat: CSB-E04675h), plasma protease C1 inhibitor (SERPING1) kits (Cat: CSB-EL021086HU), insulin-like growth factor-binding protein 5 (IGFBP5) kits (Cat: CSB-EL010901HU), tripartite motif-containing protein 28 (TRIM28) kits (Cat: CSB-EL024502HU), and fatty acid-binding protein 5 (FABP5) kits (Cat: CSB-EL007946HU) were purchased from Cusabio (Wuhan, China).

Techniques: Biomarker Discovery, Comparison

Characterization of myeloid cell subsets and identification of CD5L⁺ macrophages as potential migrasome-responsive cells. ( A ) UMAP visualization showing the reclustering of myeloid cells into 10 distinct subpopulations. ( B ) Heatmap displaying the expression profiles of representative marker genes for each myeloid subset. ( C ) Bar plot showing the relative abundance of each myeloid subpopulation in normoxic versus hypoxic migrasome-treated groups. A notable 8-fold increase in the proportion of CD5L⁺ macrophages was observed in the hypoxic group. ( D ) Gene Set Variation Analysis (GSVA) indicating significant activation of the complement signaling pathway in CD5L⁺ macrophages. ( E ) Chord diagram depicting inferred cell–cell communication networks, highlighting potential interactions between CD5L⁺ macrophages and fibroblasts, T cells, and other immune cells via GDF signaling. ( F ) Activation IGF signaling pathway network mediated crosstalk between CD5L⁺ macrophages and epithelial tumor cells. ( G ) In the IGF signaling pathway network, CD5L⁺ macrophages exhibit specific overexpression of IGF1. ( H ) Among the six macrophage cell-types, CD5L⁺ macrophages exhibit specific overexpression of CD5L

Journal: Journal of Translational Medicine

Article Title: Hypoxic migrasomes drive colorectal cancer liver metastasis by mediating CD5L + macrophage efferocytosis via NRP2/PROX1 axis

doi: 10.1186/s12967-025-07485-0

Figure Lengend Snippet: Characterization of myeloid cell subsets and identification of CD5L⁺ macrophages as potential migrasome-responsive cells. ( A ) UMAP visualization showing the reclustering of myeloid cells into 10 distinct subpopulations. ( B ) Heatmap displaying the expression profiles of representative marker genes for each myeloid subset. ( C ) Bar plot showing the relative abundance of each myeloid subpopulation in normoxic versus hypoxic migrasome-treated groups. A notable 8-fold increase in the proportion of CD5L⁺ macrophages was observed in the hypoxic group. ( D ) Gene Set Variation Analysis (GSVA) indicating significant activation of the complement signaling pathway in CD5L⁺ macrophages. ( E ) Chord diagram depicting inferred cell–cell communication networks, highlighting potential interactions between CD5L⁺ macrophages and fibroblasts, T cells, and other immune cells via GDF signaling. ( F ) Activation IGF signaling pathway network mediated crosstalk between CD5L⁺ macrophages and epithelial tumor cells. ( G ) In the IGF signaling pathway network, CD5L⁺ macrophages exhibit specific overexpression of IGF1. ( H ) Among the six macrophage cell-types, CD5L⁺ macrophages exhibit specific overexpression of CD5L

Article Snippet: The pellet was resuspended in 200 μL antibody dilution buffer (2% FBS in 1× PBS) and incubated with 0.5 μg CD5L antibody (BAF2834, R&D Systems) at 4 °C for 60 min in the dark.

Techniques: Expressing, Marker, Activation Assay, Over Expression

Phagocytic activity and immunofluorescence validation of CD5L⁺ macrophages in CRC liver metastases following migrasome treatment. ( A ) UMAP blot showing the expression of migrasome marker TSPAN4 in myeloid subsets. ( B ) Boxplot showing efferocytosis scores across the 10 identified myeloid cell subtypes. ( C ) Violin plots depicting the expression of efferocytosis markers CD300B, MERTK, and CD300D across 10 distinct myeloid cell subtypes. ( D ) UMAP plots displaying the expression patterns of three efferocytosis-associated marker genes specifically enriched in CD5L⁺ macrophages. ( E ) Immunofluorescence staining of tumor tissues from MC38-tumor bearing mice showing colocalization of CD163, CD5L, and the migrasome marker MERTK in both treatment groups. Increased MERTK expression is observed in the hypoxic group, indicating enhanced migrasome targeting of CD5L⁺ macrophages

Journal: Journal of Translational Medicine

Article Title: Hypoxic migrasomes drive colorectal cancer liver metastasis by mediating CD5L + macrophage efferocytosis via NRP2/PROX1 axis

doi: 10.1186/s12967-025-07485-0

Figure Lengend Snippet: Phagocytic activity and immunofluorescence validation of CD5L⁺ macrophages in CRC liver metastases following migrasome treatment. ( A ) UMAP blot showing the expression of migrasome marker TSPAN4 in myeloid subsets. ( B ) Boxplot showing efferocytosis scores across the 10 identified myeloid cell subtypes. ( C ) Violin plots depicting the expression of efferocytosis markers CD300B, MERTK, and CD300D across 10 distinct myeloid cell subtypes. ( D ) UMAP plots displaying the expression patterns of three efferocytosis-associated marker genes specifically enriched in CD5L⁺ macrophages. ( E ) Immunofluorescence staining of tumor tissues from MC38-tumor bearing mice showing colocalization of CD163, CD5L, and the migrasome marker MERTK in both treatment groups. Increased MERTK expression is observed in the hypoxic group, indicating enhanced migrasome targeting of CD5L⁺ macrophages

Article Snippet: The pellet was resuspended in 200 μL antibody dilution buffer (2% FBS in 1× PBS) and incubated with 0.5 μg CD5L antibody (BAF2834, R&D Systems) at 4 °C for 60 min in the dark.

Techniques: Activity Assay, Immunofluorescence, Biomarker Discovery, Expressing, Marker, Staining